SLNO Soleno Therapeutics Inc

Soleno Therapeutics to Participate in Upcoming June Conferences

Soleno Therapeutics to Participate in Upcoming June Conferences

REDWOOD CITY, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in June:

Jefferies Global Healthcare Conference

Presentation Date: Wednesday, June 4, 2025 at 10:30 AM ET

Presentation Format: Corporate Presentation

Webcast: 

Goldman Sachs 46th Healthcare Conference

Presentation Date: Tuesday, June 10, 2025 at 8:40 AM ET

Presentation Format: Corporate Presentation

Webcast: 

A replay of both events will be available in the Investors section on the Company’s website at .

About Soleno Therapeutics, Inc.

Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The Company’s first commercial product, VYKAT™ XR (diazoxide choline) extended-release tablets, formerly known as DCCR, is a once-daily oral treatment for hyperphagia in adults and children four years of age and older with Prader-Willi syndrome. For more information, please visit .

Corporate Contact:

Brian Ritchie

LifeSci Advisors, LLC

212-915-2578



EN
21/05/2025

Underlying

SLNOSoleno Therapeutics Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Soleno Therapeutics Inc

 PRESS RELEASE
Free
SLNO Soleno Therapeu...

Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and...

Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM XR and reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 and Recent Corporate Highlights Announced launch of VYKAT XR and commencement of patient treatments on April 14, 2...

August 6, 2025 1 EN
 PRESS RELEASE
Free
SLNO Soleno Therapeu...

Soleno Therapeutics to Report Second Quarter 2025 Financial Results on...

Soleno Therapeutics to Report Second Quarter 2025 Financial Results on August 6, 2025, at 4:30 PM ET REDWOOD CITY, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its second quarter 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Wednesday, August 6, 2025. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results an...

July 28, 2025 1 EN
 PRESS RELEASE
Free
SLNO Soleno Therapeu...

Soleno Therapeutics Announces Pricing of $200 Million Public Offering ...

Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (Nasdaq: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it has priced its previously announced underwritten public offering of 2,352,941 shares of its common stock at a price to the public of $85.00 per share. All of the shares are being sold by Soleno. In addition, Soleno has granted the underwriters a 30-day option to purchase up to an ad...

July 10, 2025 1 EN
 PRESS RELEASE
Free
SLNO Soleno Therapeu...

Soleno Therapeutics Announces Proposed $200 Million Public Offering of...

Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (Nasdaq:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it intends to offer and sell $200 million of shares of its common stock in an underwritten public offering. In addition, Soleno intends to grant the underwriters a 30-day option to purchase up to an additional $30 million of shares of common stock. The proposed public offering is subject ...

July 10, 2025 1 EN
 PRESS RELEASE
Free
SLNO Soleno Therapeu...

Soleno Therapeutics Announces Preliminary Financial and Operational Re...

Soleno Therapeutics Announces Preliminary Financial and Operational Results for the Second Quarter Ended June 30, 2025 REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (Nasdaq: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today certain preliminary unaudited financial and operational results for the three months ended June 30, 2025: Soleno expects its net revenue from the sales of VYKATTM XR, for the three months ended June 30, 2025 to be between $31.0 million and $33.0 million....

July 10, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch